|
|||||
|
|
| 分子影像学肿瘤疗效评价标准及应用 | |
| 引用本文： | 鲍晓,;程竞仪[综述],;章英剑[审校]. 分子影像学肿瘤疗效评价标准及应用[J]. 上海医学影像, 2014, 0(3): 165-171 |
| 作者姓名： | 鲍晓, 程竞仪[综述], 章英剑[审校] |
| 作者单位： | [1]复旦大学附属肿瘤医院核医学科,复旦大学上海医学院肿瘤学系,上海200032; [2]上海市质子重离子医院核医学科,上海201321 |
| 摘 要： | 基于肿瘤体积变化的实体瘤疗效评价标准--RECIST标准，具有一定的滞后性，难以满足对临床各种治疗手段的评价。18F-脱氧葡萄糖（18F-FDG）PET分子影像能反映细胞葡萄糖代谢，实现生物学水平早期评价肿瘤疗效，评价标准从EORTC、PERCIST到PREDIST，根据临床需求不断完善；更有针对骨转移瘤的MDA标准。该文详细概述以上4种分子影像学标准的评价方法及其临床应用。 |
| 关 键 词： | 实体瘤 骨转移瘤 疗效评价 EORTC标准 PERCIST标准 PREDIST标准 MDA标准 |
Introduction and clinical application of molecular imaging response evaluation criteria in solid tumors and bone metastases |
|
| Affiliation: | BAO Xiao, CHENG Jing-yi, ZHANG Ying-jian (1.Department of Nuclear Medicine, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; 2.Department of Nuclear Medicine, Shanghai Proton and Heavy Ion Center, Shanghai 201321, China) |
| Abstract: | With the development of diversification and individualization of therapy, it was found that the changes of tumor lesions are not consistent with the prognosis. RECIST criteria, which are based on the anatomical changes, always lag behind. Thus it is necessary to establish accurate, effective and feasible evaluation criteria. Molecular imaging can evaluate tumor response from glucose metabolism, including EORTC, PERCIST, PREDIST and MDA criteria. This paper introduces four evaluation criteria and their clinical application. |
| Keywords: | Solid tumor Bone metastasis Response evaluation EORTC criteria PERCIST criteria PREDIST criteria MDA criteria |
| 本文献已被 维普 等数据库收录！ | |